Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection
- 30 April 2007
- Vol. 25 (17) , 3302-3310
- https://doi.org/10.1016/j.vaccine.2007.01.010
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Intranasal Vaccination with Recombinant Adeno-Associated Virus Type 5 against Human Papillomavirus Type 16 L1Journal of Virology, 2006
- A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigensVaccine, 2004
- Comparison of HPV DNA vaccines employing intracellular targeting strategiesGene Therapy, 2004
- Adjuvant Effects of Cholera Toxin b Subunit on Immune Response to Recombinant Thyrotropin Receptor in MiceJournal of Autoimmunity, 2000
- Papillomavirus infections — a major cause of human cancersBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1996
- A Nontoxic Chimeric Cholera Toxin AnalogaAnnals of the New York Academy of Sciences, 1996
- Studies on in Vivo Induction of Cytotoxic T Lymphocyte Responses by Synthetic Peptides from E6 and E7 Oncoproteins of Human Papillomavirus Type 16Viral Immunology, 1995
- Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbuminVaccine, 1994
- Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cellsEuropean Journal of Immunology, 1993
- Introduction of soluble protein into the class I pathway of antigen processing and presentationCell, 1988